◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Acutaas Chemicals Limited (ACUTAAS) Revenue 2022–2026

Name: Acutaas Chemicals Limited (ACUTAAS) revenue history 2022-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Acutaas Chemicals Limited annual revenue for fiscal 2026 was ₹13.3 billion, an increase of 32.9% from ₹10.0 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

ACUTAAS Annual Revenue

Revenue (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹13.3B	₹10.0B	₹7.1B	₹6.1B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ACUTAAS Quarterly Revenue

Revenue (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31	2024-12-31
Total Revenue	₹3.3B	₹4.2B	₹3.9B	₹2.1B	₹3.0B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

7966 Revenue — LINTEC Corporation
4208 Revenue — UBE Corporation
4966 Revenue — C.Uyemura & Co.,Ltd.
4043 Revenue — Tokuyama Corporation
8098 Revenue — Inabata & Co.,Ltd.
4046 Revenue — Osaka Soda Co., Ltd.

More ACUTAAS metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All ACUTAAS financial statements → Interactive ACUTAAS charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.